FDA Clears New Romidepsin Formulation for Lymphoma Treatment

The U.S. FDA has approved a new ready-to-use romidepsin injection solution by Amneal Pharmaceuticals. This formulation is intended for adult patients with cutaneous T-cell lymphoma who have undergone previous systemic therapy. The approval offers a more convenient treatment option and includes a period of market exclusivity for Amneal.